Are You Thinking About Investing In Adicet Bio (ACET)?

Small-cap Healthcare company Adicet Bio has logged a -37.9% change today on a trading volume of 5,080,923. The average volume for the stock is 616,768.

Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. Based in Boston, United States the company has 86 full time employees and a market cap of $459,794,432.

The company is now trading -61.8% away from its average analyst target price of $28.09 per share. The 11 analysts following the stock have set target prices ranging from $21 to $34, and on average give Adicet Bio a rating of strong buy.

Over the last year, ACET shares have gone up 15.2%, which represents a difference of 30.9% when compared to the S&P 500. The stock's 52 week high is $21.87 per share whereas its 52 week low is $9.38. With its operating margins declining an average -595.2% over the last four years, Adicet Bio may not have a strong enough business to keep this trend.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.